Abstract
Group W135 polysaccharide vaccines were licensed without efficacy trials using the serum bactericidal antibody (SBA) assay as a surrogate of protection. Standardization of group A and C SBA assays has been largely achieved. However, no such efforts have been focussed on W135. Although W135 strains have been recommended by WHO for polysaccharide production, no such recommendation are in place for use in immunoassays. Strain characterization is of importance as W135 strains may possess either an O-acetylated or de-O-acetylated polysaccharide capsule and the human immune response can vary according to the O-acetylation of the target antigen. Following conjugate or polysaccharide vaccination, few data are published with respect to complement source comparisons although both human and baby rabbit sera have been utilized with similar end points. In studies of natural immunity subcapsular antigens are primarily the target antigens and thus strain choice for use in the SBA assay is important. International standardization of assays is necessary to allow for comparisons of data over time and place.
| Original language | English |
|---|---|
| Pages (from-to) | A63-A68 |
| Journal | Vaccine |
| Volume | 25 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - 3 Sep 2007 |
| Externally published | Yes |
Bibliographical note
Funding Information:PB has received financial support for attending meetings from Wyeth Vaccines, Baxter Bioscience and Chiron Vaccines. RB has received financial support for attending meetings from, served as consultant, and performed contract research for Alexion Pharmaceuticals Inc, Baxter Bioscience, Chiron Vaccines, Fujisawa GmbH, GlaxoSmithKline, Microscience Ltd., Sanofi Pasteur, Wyeth Vaccines, Xenova Research Limited.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
Keywords
- Bactericidal
- Group W135
- Meningococcal
- Vaccine
